Skip to content

The I-KAN Study: Internet Insulin Education for Kansans

The I-KAN Study: Internet Initiation of Insulin for Type 2 Diabetes in Kansas

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01408628
Acronym
I-KAN
Enrollment
51
Registered
2011-08-03
Start date
2011-08-31
Completion date
2015-01-31
Last updated
2015-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

The primary purpose of the study is demonstration that teaching insulin management in small groups of type 2 diabetes patients in 4 weekly live Internet sessions is safe and provides an important resource for rural diabetes care providers who may otherwise, because of lack of time or staff, not be able to put patients on insulin who need it.

Detailed description

The proposed project will test in a limited number of rural and semi-rural sites in the state of Kansas an innovative model of synchronous (live) Internet initiation and intensification of once daily basal insulin glargine or detemir in type 2 diabetic patients that can be deployed statewide in a subsequent larger study (R18). The study's specific aims are to 1) develop a synchronous (live) interactive Internet-administered course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve a HbA1c \< 7.0% using a treat-to-target algorithm; and 2) to assess for the Internet patients selected clinical and psychometric outcomes. These will include HbA1c, frequency and severity of hypoglycemia, psychological resistance to insulin treatment, diabetes quality of life, and treatment satisfaction. The study builds upon the findings of the Treat-to-Target and INITIATE trials, as well as on successful Internet interventions for weight management, and both lays the conceptual foundation and gathers the expertise to successfully apply for the R18, which will have as primary aims addressing of delays to insulin therapy documented in the DAWN study and cost effectiveness analysis of the Internet intervention. The study hopes to show that Internet teaching of basal insulin therapy is comparable to traditional insulin management with respect to safety and effectiveness as measured against expected (published) results for frequency of hypoglycemia and percent of patients reaching target. Psychometric outcomes are exploratory - and hypothesis generating with respect to the subsequent R18 application.

Interventions

BEHAVIORALInternet Insulin Education

Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
David Robbins, MD
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* T2DM, meets provider criteria for insulin initiation; starting or having started insulin treatment no longer than six months prior to enrollment OR has not yet committed to starting insulin but has agreed to participate in the education * broadband Internet and experience with logging into a password-protected site (e.g., eCommerce or social networking); * ability to purchase or otherwise acquire glargine/detemir insulin and testing supplies.

Exclusion criteria

* Use of oral glucocorticoids or second generation anti-psychotics; * previous use of self-administered insulin more than six months prior to enrollment; * gestational diabetes or other endocrine conditions causing hyperglycemia; treatment for a malignant condition other than basal cell carcinoma in situ within prior two years; * renal insufficiency (AST/ALT \>2 or concurrent liver disease except NASH); * pregnant or planning to become pregnant within 6 months; * HbA1c \< 7.0% or ongoing weight loss or persistent fasting hyperglycemia \> 250 mg/dl.

Design outcomes

Primary

MeasureTime frameDescription
Frequency of Hypoglycemia6-month follow up period following the Internet InterventionHypoglycemia was defined in the study as either a blood glucose reading \<70 mg/dL or symptomatic to the patient/subject.

Secondary

MeasureTime frameDescription
Change in HbA1cChange from Baseline through Month 6 of follow-up periodChange in HbA1c (average measure of the % of glycosolated hemoglobin in the blood over the past 3 months) from baseline to end of follow up period.
Severity of Self-reported Hypoglycemia6 MonthsSeverity was defined by the scale used by the DCCT: grade 1 - subject was able to recognize and treat appropriately without assistance; grade 2 - subject required help from another person either to recognize or recognize/treat; grade 3 - subject required injection of glucagon or treatment in ER

Countries

United States

Participant flow

Participants by arm

ArmCount
Internet Insulin Education
Internet Insulin Education: Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm.
51
Total51

Withdrawals & dropouts

PeriodReasonFG000
Completed 6 Month Follow-UpLost to Follow-up3
Completed 6 Month Follow-UpProtocol Violation6
Completed 6 Month Follow-UpWithdrawal by Subject5
ConsentedWithdrawal by Subject12

Baseline characteristics

CharacteristicInternet Insulin Education
A1c Baseline8.61 Percentage (glycosolated hemoglobin)
STANDARD_DEVIATION 1.63
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
15 Participants
Age, Categorical
Between 18 and 65 years
36 Participants
Age, Continuous58.67 years
STANDARD_DEVIATION 10.54
Region of Enrollment
United States
51 participants
Sex: Female, Male
Female
27 Participants
Sex: Female, Male
Male
24 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
10 / 39
serious
Total, serious adverse events
0 / 39

Outcome results

Primary

Frequency of Hypoglycemia

Hypoglycemia was defined in the study as either a blood glucose reading \<70 mg/dL or symptomatic to the patient/subject.

Time frame: 6-month follow up period following the Internet Intervention

Population: Subjects who both completed the Internet intervention AND the 6 months of follow up

ArmMeasureValue (MEAN)Dispersion
Internet Insulin EducationFrequency of Hypoglycemia6.88 incidents per person-yearStandard Deviation 11.2
Secondary

Change in HbA1c

Change in HbA1c (average measure of the % of glycosolated hemoglobin in the blood over the past 3 months) from baseline to end of follow up period.

Time frame: Change from Baseline through Month 6 of follow-up period

Population: Subjects who both completed the Internet intervention and the six months of follow up

ArmMeasureValue (MEAN)Dispersion
Internet Insulin EducationChange in HbA1c-1.33 percentage of glycosolated hemoglobinStandard Deviation 1.44
Secondary

Severity of Self-reported Hypoglycemia

Severity was defined by the scale used by the DCCT: grade 1 - subject was able to recognize and treat appropriately without assistance; grade 2 - subject required help from another person either to recognize or recognize/treat; grade 3 - subject required injection of glucagon or treatment in ER

Time frame: 6 Months

Population: Subjects who completed both the Internet intervention and the 6 months of follow up

ArmMeasureGroupValue (NUMBER)
Internet Insulin EducationSeverity of Self-reported HypoglycemiaGrade 1141 incidents (count)
Internet Insulin EducationSeverity of Self-reported HypoglycemiaGrade 21 incidents (count)
Internet Insulin EducationSeverity of Self-reported HypoglycemiaGrade 30 incidents (count)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026